| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b58f981963f6d55d627139e778c4ef7b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2002-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_566a9a1843400f0dbd79dbe09067b616
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b74a5c863f32d0b7e9b91ab0cbced756
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e44f2b3463ce9b8407130aa718fb27e1 |
| publicationDate |
2003-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
FR-2834900-A1 |
| titleOfInvention |
NOVEL COMPOSITIONS WITH ANTI-IGF-IR AND ANTI-EGFR ACTIVITY AND THEIR APPLICATIONS |
| abstract |
The present invention relates to new compositions comprising at least a first compound capable of binding specifically to the human growth factor I receptor related to insulin IGF-IR and of inhibiting its activity, and a second compound capable of bind specifically to the human epidermal growth factor EGFR receptor and inhibit its activity, composition in which said first compound is in particular an anti-IGF-IR antibody whose amino acid and nucleic acid sequences coding for CDR of this antibody, have been characterized here. The invention also includes these compositions as combination products for simultaneous, separate or spread over time use, in particular in combination with anticancer agents. The invention also includes the use of these compositions as a medicament for the prophylactic and / or therapeutic treatment of cancers as well as methods of diagnosing diseases linked to the overexpression of the IGF-IR and EGFR receptor. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8062886-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2405270-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7667021-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7217796-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8017735-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7326567-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008076278-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2281841-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2283831-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7811562-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7851181-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7847068-B2 |
| priorityDate |
2002-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |